Centauri expands Series A to tackle superbugs
UK-based biotech company Centauri has extended its Series A funding round to a total of £30 million after securing fresh investment from the AMR Action Fund, a global initiative focused on combating antimicrobial resistance (AMR). The capital injection will accelerate the development of new therapies aimed at drug‑resistant bacterial infections, a growing threat to health systems worldwide.
Strategic backing from AMR Action Fund
The participation of the AMR Action Fund signals strong confidence in Centauri‘s pipeline and technology platform. The fund, supported by leading pharmaceutical companies and global health institutions, was created to bridge the financing gap for late‑stage antibiotic and anti‑infective innovation.
By joining the round, the AMR-focused investor is expected to provide not only capital but also deep regulatory, clinical and market‑access expertise. This support will be critical as Centauri moves its most advanced candidates toward clinical trials and eventual commercialisation.
Targeting drug‑resistant infections
Drug‑resistant infections are estimated to cause hundreds of thousands of deaths annually, with projections suggesting they could claim millions of lives per year by 2050 if new treatments are not developed. Traditional antibiotic R&D has struggled due to high costs, complex clinical pathways and limited commercial returns, leaving a dangerous gap in the global pipeline.
Centauri is developing novel molecules and treatment approaches designed to overcome bacterial resistance mechanisms and reduce the likelihood of future resistance. The newly expanded funding will be used to advance preclinical programmes, scale up laboratory capabilities and strengthen partnerships with hospitals and research institutions.
Positioning within the biotech and health-security landscape
The extended £30 million round positions Centauri as one of the better‑capitalised early‑stage players in the AMR field, a niche that has recently attracted renewed attention from both venture capital and public‑health investors. The deal underscores a broader recognition that health security depends on sustained investment in next‑generation anti‑infective therapies, not only pandemic vaccines.
With the backing of the AMR Action Fund and other specialist investors, Centauri aims to translate its scientific platform into clinically validated products that can be deployed against some of the most dangerous resistant pathogens facing hospitals and communities today.